Publications 2024

Holm S, Michelsen AE, Schultz NH, Ueland T, Reikvam H, Holme PA, Aukrust P, Halvorsen B (2024)
Human papilloma virus vaccine induced thrombocytopenia accompanied by a wide spectrum of reversible inflammatory responses - a case report
Scand J Clin Lab Invest, 84 (6), 425-427
DOI 10.1080/00365513.2024.2400663, PubMed 39264796

Holme PA, Blatný J, Chowdary P, Lassila R, O'Connell N, Hermans C, Álvarez Román MT, Négrier C, Coppola A, Oldenburg J (2024)
Moving towards Normalization of haemostasis and health equity: Evolving treatment goals for haemophilia A
Haemophilia, 30 (5), 1109-1114
DOI 10.1111/hae.15031, PubMed 38986684

Holme PA, Poulsen LH, Tueckmantel C, Maas Enriquez M, Alvarez Román MT, De Cristofaro R (2024)
Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study
Haemophilia, 30 (2), 388-394
DOI 10.1111/hae.14930, PubMed 38229269

Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme PA, Álvarez-Román MT, Biron-Andréani C, Malmström H, Bystrická L, Lethagen S, A‐SURE Study Group (2024)
Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study
Eur J Haematol (in press)
DOI 10.1111/ejh.14309, PubMed 39434416

Qvigstad C, Sørensen LQ, Tjønnfjord GE, Holme PA, Age-related DeVelopments ANd ComorbiditiEs in hemophilia Working Group (2024)
The association between unemployment and treatment among adults with hemophilia
Res Pract Thromb Haemost, 8 (5), 102514
DOI 10.1016/j.rpth.2024.102514, PubMed 39188890

Reding MT, Lalezari S, Kenet G, Di Minno G, Ducore J, Solms A, Shah A, Holme PA, Poulsen LH, Meijer K, Simpson M, Mancuso ME (2024)
Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review
Drugs R D, 24 (3), 359-381
DOI 10.1007/s40268-024-00481-7, PubMed 39162954

Reding MT, Simpson M, Ducore J, Holme PA, Maas Enriquez M, Mancuso ME (2024)
Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII
Acta Haematol, 1-10 (in press)
DOI 10.1159/000538702, PubMed 38599195

Publications 2023

Arvanitakis A, Holme PA, Berntorp E, Astermark J (2023)
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia A
Haemophilia, 29 (4), 1032-1038
DOI 10.1111/hae.14806, PubMed 37252898

Astermark J, Baghaei F, Strandberg K, Toplican PG, Birkedal MF, Grahn EE, Hansson C, Kampmann P, Lehtinen AE, Täckström K, Holme PA, Magnusson M (2023)
Infrastructural considerations of implementing gene therapy for hemophilia in the Nordic context
Ther Adv Hematol, 14, 20406207231202306
DOI 10.1177/20406207231202306, PubMed 37859645

Ettingshausen CE, Hermans C, Holme PA, Cid AR, Khair K, Oldenburg J, Négrier C, Botha J, Lelli A, Windyga J (2023)
Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study
Ther Adv Hematol, 14, 20406207231184323
DOI 10.1177/20406207231184323, PubMed 37529276

Hermans C, Astermark J, Carvalho M, Dolan G, d'Oiron R, Fontana P, Holme PA, Kenet G, Klamroth R, Mancuso ME, Marquardt N, Nunez R, Katsarou O, Pabinger-Fasching I, Quintavalle G, Rodgers R, van der Valk P, Windyga J, Jimenez Yuste V, Preložnik Zupan I (2023)
Prevalence of COVID-19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: A survey from Europe
Haemophilia, 29 (3), 913-916
DOI 10.1111/hae.14761, PubMed 36802089

Hillarp A, Holme PA, Wåland EP, Le MS, Henriksson CE, Tjønnfjord GE, Måseide RJ (2023)
Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII
J Thromb Haemost, 21 (10), 2771-2775
DOI 10.1016/j.jtha.2023.07.019, PubMed 37543216

Jørgensen OJ, Steineger JE, Hillarp A, Pareli Wåland E, Holme PA, Heimdal K, Dheyauldeen S (2023)
Elevated FVIII levels in hereditary hemorrhagic telangiectasia: Implications for clinical management
Laryngoscope Investig Otolaryngol, 9 (1), e1196
DOI 10.1002/lio2.1196, PubMed 38362186

Matlary RED, Grydeland M, Glosli H, Rueegg CS, Holme PA (2023)
Physical activity in Norwegian teenagers and young adults with haemophilia A compared to general population peers
Haemophilia, 29 (2), 658-667
DOI 10.1111/hae.14752, PubMed 36723510

Matlary RED, Grydeland M, Glosli H, Rueegg CS, Holme PA (2023)
Factors associated with physical activity in young people with haemophilia A on prophylaxis
Haemophilia, 29 (3), 900-909
DOI 10.1111/hae.14776, PubMed 36913380

Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Tjønnfjord GE, Holme PA (2023)
Health-related quality of life and physical activity in Nordic patients with moderate haemophilia A and B (the MoHem study)
Haemophilia, 30 (1), 98-105
DOI 10.1111/hae.14899, PubMed 37983883

Reding MT, Pabinger I, Holme PA, Maas Enriquez M, Mancuso ME, Lalezari S, Miesbach W, Di Minno G, Klamroth R, Hermans C (2023)
Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study
Ther Adv Hematol, 14, 20406207231166779
DOI 10.1177/20406207231166779, PubMed 37113811

Warlo EMK, Kalstad AA, Myhre PL, Solheim S, Arnesen H, Tveit A, Holme PA, Seljeflot I, Bratseth V (2023)
von Willebrand factor, ADAMTS-13, and thrombospondin 1 in relation to clinical outcomes in elderly patients with a recent myocardial infarction
Res Pract Thromb Haemost, 7 (4), 100164
DOI 10.1016/j.rpth.2023.100164, PubMed 37255854

Publications 2022

Arvanitakis A, Holme PA, Berntorp E, Astermark J (2022)
Clinical outcome and adherence rate in Scandinavian patients with intermediate-intensity prophylaxis before and after the switch of standard half-life FVIII products to BAY 81-8973
Haemophilia, 28 (2), 223-229
DOI 10.1111/hae.14489, PubMed 35005818

Hetland G, Fagerhol MK, Wiedmann MKH, Søraas AVL, Mirlashari MR, Nissen-Meyer LSH, Istre MS, Holme PA, Schultz NH (2022)
Elevated NETs and Calprotectin Levels after ChAdOx1 nCoV-19 Vaccination Correlate with the Severity of Side Effects
Vaccines (Basel), 10 (8)
DOI 10.3390/vaccines10081267, PubMed 36016155

Kihlberg K, Baghaei F, Bruzelius M, Funding E, Holme PA, Lassila R, Martin M, Nummi V, Ranta S, Strandberg K, Andersson NG, Berntorp E, Astermark J (2022)
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications
Thromb Res, 217, 22-32
DOI 10.1016/j.thromres.2022.06.015, PubMed 35842956

Klamroth R, Ay C, De Moerloose P, Fontana P, Windyga J, Astermark J, Berntorp E, Carvalho M, Dolan G, Hermans C, Holme PA, Kenet G, Mancuso ME, Marquardt N, Nunez R, Pabinger I, Rodgers R, Valk PV, Yuste VJ, Zupan IP (2022)
Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A - A modified Delphi consensus by the ADVANCE Working Group
Haemophilia, 29 (1), 21-32
DOI 10.1111/hae.14674, PubMed 36271497

Klintman J, Akesson KE, Holme PA, Fischer K (2022)
Bone mineral density in haemophilia - a multicentre study evaluating the impact of different replacement regimens
Haemophilia, 28 (2), 239-246
DOI 10.1111/hae.14487, PubMed 34994489

Lehtinen AE, Baghaei F, Astermark J, Holme PA (2022)
Surgical outcomes in patients with haemophilia A or B receiving extended half-life recombinant factor VIII and IX Fc fusion proteins: Real-world experience in the Nordic countries
Haemophilia, 28 (5), 713-719
DOI 10.1111/hae.14585, PubMed 35575446

Matlary RED, Holme PA, Glosli H, Rueegg CS, Grydeland M (2022)
Comparison of free-living physical activity measurements between ActiGraph GT3X-BT and Fitbit Charge 3 in young people with haemophilia
Haemophilia, 28 (6), e172-e180
DOI 10.1111/hae.14624, PubMed 35830613

Schultz NH, Søraas AVL, Sørvoll IH, Akkök ÇA, Vetlesen A, Bhamra JS, Ahlen MT, Holme PA, Aamodt AH, Skagen K, Skattør TH, Skjelland M, Wiedmann MK (2022)
Vaccine associated benign headache and cutaneous hemorrhage after ChAdOx1 nCoV-19 vaccine: A cohort study
J Stroke Cerebrovasc Dis, 32 (1), 106860
DOI 10.1016/j.jstrokecerebrovasdis.2022.106860, PubMed 36403363

Szanto T, Zetterberg E, Ramström S, Leinøe EB, Holme PA, Antovic JP, Holmström M, Onundarson PT, Pikta M, Vaide I, Olsson A, Magnusson M, Kärkkäinen S, Bitar M, Poulsen LH, Lassila R, Nordic Haemophilia Council (2022)
Platelet function testing: Current practice among clinical centres in Northern Europe
Haemophilia, 28 (4), 642-648
DOI 10.1111/hae.14578, PubMed 35510959

Ueland T, Hausberg I, Mørtberg TV, Dahl TB, Lerum TV, Michelsen A, Ranheim T, Nezvalova Henriksen K, Dyrhol-Riise AM, Holme PA, Aaløkken TM, Skjønsberg OH, Barratt-Due A, Ahlén MT, Aukrust P, Halvorsen B (2022)
Anti-PF4/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology
Platelets, 33 (4), 640-644
DOI 10.1080/09537104.2022.2042238, PubMed 35225150

Warlo EMK, Bratseth V, Pettersen AR, Holme PA, Arnesen H, Seljeflot I, Opstad TB (2022)
Genetic Variation in ADAMTS13 is Related to VWF Levels, Atrial Fibrillation and Cerebral Ischemic Events
Clin Appl Thromb Hemost, 28, 10760296221141893
DOI 10.1177/10760296221141893, PubMed 36474435

Publications 2021

Astermark J, Ay C, Carvalho M, D'Oiron R, Moerloose P, Dolan G, Fontana P, Hermans C, Holme PA, Katsarou O, Kenet G, Klamroth R, Mancuso ME, Marquardt N, Núñez R, Pabinger I, Tait R, Valk PV (2021)
New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia
Thromb Haemost, 122 (6), 905-912
DOI 10.1055/a-1642-4067, PubMed 34507368

Holm S, Kared H, Michelsen AE, Kong XY, Dahl TB, Schultz NH, Nyman TA, Fladeby C, Seljeflot I, Ueland T, Stensland M, Mjaaland S, Goll GL, Nissen-Meyer LS, Aukrust P, Skagen K, Gregersen I, Skjelland M, Holme PA, Munthe LA, Halvorsen B (2021)
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia
Eur Heart J, 42 (39), 4064-4072
DOI 10.1093/eurheartj/ehab506, PubMed 34405870

Holstein K, Le Quellec S, Klamroth R, Batorova A, Holme PA, Jiménez-Yuste V, Astermark J (2021)
Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
Haemophilia, 28 (2), 215-222
DOI 10.1111/hae.14470, PubMed 34918839

Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA (2021)
Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
Haemophilia, 27 (4), 519-530
DOI 10.1111/hae.14322, PubMed 33988293

Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H (2021)
Thrombosis and thrombocytopenia after HPV vaccination
J Thromb Haemost, 20 (3), 700-704
DOI 10.1111/jth.15604, PubMed 34817130

Måseide RJ, Berntorp E, Astermark J, Hansen J, Olsson A, Bruzelius M, Frisk T, Aspdahl M, Nummi V, Tjønnfjord GE, Holme PA (2021)
Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study
Haemophilia, 27 (2), e253-e259
DOI 10.1111/hae.14245, PubMed 33550602

Måseide RJ, Berntorp E, Nummi V, Lassila R, Tjønnfjord GE, Holme PA (2021)
Bleeding phenotype of patients with moderate haemophilia A and B assessed by thromboelastometry and thrombin generation
Haemophilia, 27 (5), 793-801
DOI 10.1111/hae.14355, PubMed 34106506

Reding MT, Pabinger I, Holme PA, Poulsen L, Negrier C, Chalasani P, Maas Enriquez M, Wang M, Meijer K, Mancuso ME, Lalezari S (2021)
Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study
Haemophilia, 27 (3), e347-e356
DOI 10.1111/hae.14297, PubMed 33818853

Schultz NH, Fareed J, Holme PA (2021)
Investigation of the Optimal Dose aPCC in Reversing the Effect of Factor Xa Inhibitors-An In Vitro Study
Clin Appl Thromb Hemost, 27, 10760296211021156
DOI 10.1177/10760296211021156, PubMed 34060371

Schultz NH, Glosli H, Bjørnsen S, Holme PA (2021)
The effect of emicizumab and bypassing agents in patients with hemophilia - An in vitro study
Res Pract Thromb Haemost, 5 (5), e12561
DOI 10.1002/rth2.12561, PubMed 34263107

Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA (2021)
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
N Engl J Med, 384 (22), 2124-2130
DOI 10.1056/NEJMoa2104882, PubMed 33835768

Wiedmann M, Skattør T, Stray-Pedersen A, Romundstad L, Antal EA, Marthinsen PB, Sørvoll IH, Leiknes Ernstsen S, Lund CG, Holme PA, Johansen TO, Brunborg C, Aamodt AH, Schultz NH, Skagen K, Skjelland M (2021)
Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series
Front Neurol, 12, 721146
DOI 10.3389/fneur.2021.721146, PubMed 34393988

Publications 2020

Gorkom BL, Holme PA, Joch C, Rogosch T, Feussner A, McKeand W, Roberts J, van Heerde W (2020)
Pharmacokinetics and pharmacodynamics of a recombinant fusion protein linking activated coagulation factor VII with human albumin (rVIIa-FP) in patients with congenital FVII deficiency
Hematology, 25 (1), 17-25
DOI 10.1080/16078454.2019.1700329, PubMed 31852380

Kempton CL, Makris M, Holme PA (2020)
Management of comorbidities in haemophilia
Haemophilia, 27 Suppl 3, 37-45
DOI 10.1111/hae.14013, PubMed 32476243

Måseide RJ, Berntorp E, Astermark J, Olsson A, Bruzelius M, Frisk T, Nummi V, Lassila R, Tjønnfjord GE, Holme PA (2020)
Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B - The MoHem study
Haemophilia, 26 (5), 891-897
DOI 10.1111/hae.14114, PubMed 33021747

Qvigstad C, Sørensen LQ, Tait RC, de Moerloose P, Holme PA, ADVANCE Working Group (2020)
Macroscopic hematuria as a risk factor for hypertension in ageing people with hemophilia and a family history of hypertension
Medicine (Baltimore), 99 (9), e19339
DOI 10.1097/MD.0000000000019339, PubMed 32118768

Qvigstad C, Tait RC, de Moerloose P, Holme PA, ADVANCE Working Group (2020)
Hematuria in aging men with hemophilia: Association with factor prophylaxis
Res Pract Thromb Haemost, 4 (2), 309-317
DOI 10.1002/rth2.12298, PubMed 32110762

Tjønnfjord E, Holme PA, Darne B, Khelif A, Waage A, Michel M, Ben Romdhan N, Ghanima W (2020)
Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study
Br J Haematol, 191 (3), 460-465
DOI 10.1111/bjh.16672, PubMed 32342497

Publications 2019

Andersen MF, Holme PA, Tjønnfjord GE (2019)
[Surgical procedures in patients with severe haemophilia 1997–2014]
Tidsskr Nor Laegeforen, 139 (8)
DOI 10.4045/tidsskr.18.0592, PubMed 31062561

Andersen MLF, Holme PA, Tjonnfjord GE (2019)
Surgical intervention in patients with severe bleeding disorder 1997-2014
Tidsskr. Nor. Laegeforen., 139 (8), 709-712

Chowdary P, Carcao M, Holme PA, Jiménez-Yuste V, Lentz SR, Møss J, Poulsen LH, Shen C, Tosetto A, Wheeler A, Santagostino E (2019)
Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A
Res Pract Thromb Haemost, 3 (3), 542-554
DOI 10.1002/rth2.12220, PubMed 31294338

Lalezari S, Reding MT, Pabinger I, Holme PA, Negrier C, Chalasani P, Shin HJ, Wang M, Tseneklidou-Stoeter D, Maas Enriquez M (2019)
BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results
Haemophilia, 25 (6), 1011-1019
DOI 10.1111/hae.13853, PubMed 31621991

Ljungkvist M, Strandberg K, Berntorp E, Chaireti R, Holme PA, Larsen OH, Lassila R, Jouppila A, Szanto T, Zetterberg E (2019)
Evaluation of a standardized protocol for thrombin generation using the calibrated automated thrombogram: A Nordic study
Haemophilia, 25 (2), 334-342
DOI 10.1111/hae.13640, PubMed 30715788

Schultz NH, Holme PA, Henriksson CE, Mowinckel MC, Sandset PM, Bratseth V, Jacobsen EM (2019)
The influence of rivaroxaban on markers of fibrinolysis and endothelial cell activation/injury in patients with venous thrombosis
Thromb Res, 177, 154-156
DOI 10.1016/j.thromres.2019.03.010, PubMed 30903875

Publications 2018

Gamage TH, Gunnes G, Lee RH, Louch WE, Holmgren A, Bruton JD, Lengle E, Kolstad TRS, Revold T, Amundsen SS, Dalen KT, Holme PA, Tjønnfjord GE, Christensen G, Westerblad H, Klungland A, Bergmeier W, Misceo D, Frengen E (2018)
STIM1 R304W causes muscle degeneration and impaired platelet activation in mice
Cell Calcium, 76, 87-100
DOI 10.1016/j.ceca.2018.10.001, PubMed 30390422

Holme PA, Tjønnfjord GE (2018)
Continuous infusion of simoctocog alfa in haemophilia A patients undergoing surgeries
Haemophilia, 25 (1), 54-59
DOI 10.1111/hae.13625, PubMed 30394617

Qvigstad C, Tait RC, Rauchensteiner S, Berntorp E, de Moerloose P, Schutgens RE, Holme PA, ADVANCE Working Group (2018)
The elevated prevalence of risk factors for chronic liver disease among ageing people with hemophilia and implications for treatment
Medicine (Baltimore), 97 (39), e12551
DOI 10.1097/MD.0000000000012551, PubMed 30278553

Schultz NH, Holme PA, Bjørnsen S, Henriksson CE, Sandset PM, Jacobsen EM (2018)
The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
Platelets, 31 (1), 43-47
DOI 10.1080/09537104.2018.1557618, PubMed 30569801

Schultz NH, Lundblad R, Holme PA (2018)
Activated prothrombin complex concentrate to reverse the factor Xa inhibitor (apixaban) effect before emergency surgery: a case series
J Med Case Rep, 12 (1), 138
DOI 10.1186/s13256-018-1660-9, PubMed 29764497

Publications 2017

Berntorp E, Dargaud Y, Hart D, Lobet S, Mancuso ME, d'Oiron R, Perry D, Pollard D, van den Berg M, Blatný J, Chambost H, Doria AS, Holme PA, Kaczmarek R, Mantovani L, McLaughlin P, Nanayakkara L, Petrini P, Sannié T, Laane E, Maia R, Dettoraki A, Farrell A, Halimeh S, Raza S et al. (2017)
The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany
Eur J Haematol, 98 Suppl 85, 1-15
DOI 10.1111/ejh.12828, PubMed 28101938

Holme PA, Tjønnfjord GE, Batorova A (2017)
Continuous infusion of coagulation factor concentrates during intensive treatment
Haemophilia, 24 (1), 24-32
DOI 10.1111/hae.13331, PubMed 28873263

Osooli M, Steen Carlsson K, Baghaei F, Holmström M, Rauchensteiner S, Holme PA, Hvitfeldt L, Astermark J, Berntorp E (2017)
The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register
Haemophilia, 23 (3), e180-e187
DOI 10.1111/hae.13231, PubMed 28393468

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor
Thromb J, 15, 6
DOI 10.1186/s12959-017-0129-1, PubMed 28239301

Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA (2017)
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII in apixaban-treated patients in vitro
Res Pract Thromb Haemost, 1 (1), 49-56
DOI 10.1002/rth2.12015, PubMed 30046673

Publications 2016

Barratt-Due A, Fløisand Y, Orrem HL, Kvam AK, Holme PA, Bergseth G, Tjønnfjord GE, Mollnes TE (2016)
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
Rheumatology (Oxford), 55 (7), 1337-9
DOI 10.1093/rheumatology/kew040, PubMed 27105662

Berger K, Schopohl D, Lowe G, Holme PA, Tait RC, Combescure C, Rauchensteiner S, Klamroth R (2016)
How to compare cardiovascular disease and risk factors in elderly patients with haemophilia with the general population
Haemophilia, 22 (5), e406-16
DOI 10.1111/hae.13069, PubMed 27650262

Haig Y, Enden T, Grøtta O, Kløw NE, Slagsvold CE, Ghanima W, Sandvik L, Hafsahl G, Holme PA, Holmen LO, Njaaastad AM, Sandbæk G, Sandset PM, CaVenT Study Group (2016)
Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial
Lancet Haematol, 3 (2), e64-71
DOI 10.1016/S2352-3026(15)00248-3, PubMed 26853645

James PD, Mahlangu J, Bidlingmaier C, Mingot-Castellano ME, Chitlur M, Fogarty PF, Cuker A, Mancuso ME, Holme PA, Grabell J, Satkunam N, Hopman WM, Mathew P, Global Emerging HEmostasis Experts Panel (GEHEP) (2016)
Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study
Haemophilia, 22 (6), 912-918
DOI 10.1111/hae.13089, PubMed 27868369

Publications 2015

Fogarty PF, Mancuso ME, Kasthuri R, Bidlingmaier C, Chitlur M, Gomez K, Holme PA, James P, Kruse-Jarres R, Mahlangu J, Mingot-Castellano ME, Soni A, Global Emerging Hemophilia Panel (GEHEP) (2015)
Presentation and management of acute coronary syndromes among adult persons with haemophilia: results of an international, retrospective, 10-year survey
Haemophilia, 21 (5), 589-97
DOI 10.1111/hae.12652, PubMed 25689278

Ghanima W, Khelif A, Waage A, Michel M, Tjønnfjord GE, Romdhan NB, Kahrs J, Darne B, Holme PA, RITP study group (2015)
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
Lancet, 385 (9978), 1653-61
DOI 10.1016/S0140-6736(14)61495-1, PubMed 25662413

Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, de Moerloose P, ADVANCE Working Group (2015)
Hypertension, haematuria and renal functioning in haemophilia - a cross-sectional study in Europe
Haemophilia, 22 (2), 248-255
DOI 10.1111/hae.12847, PubMed 27880029

Valentino LA, Holme PA (2015)
Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?
Haemophilia, 21 (6), 709-14
DOI 10.1111/hae.12723, PubMed 26036756

Publications 2014

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233

Kristiansen A, Brandt L, Agoritsas T, Akl EA, Berge E, Bondi J, Dahm AE, Granan LP, Halvorsen S, Holme PA, Flem Jacobsen A, Jacobsen EM, Neumann I, Sandset PM, Sætre T, Tveit A, Vartdal T, Guyatt G, Vandvik PO (2014)
Adaptation of trustworthy guidelines developed using the GRADE methodology: a novel five-step process
Chest, 146 (3), 727-734
DOI 10.1378/chest.13-2828, PubMed 25180723

Misceo D, Holmgren A, Louch WE, Holme PA, Mizobuchi M, Morales RJ, De Paula AM, Stray-Pedersen A, Lyle R, Dalhus B, Christensen G, Stormorken H, Tjønnfjord GE, Frengen E (2014)
A dominant STIM1 mutation causes Stormorken syndrome
Hum Mutat, 35 (5), 556-64
DOI 10.1002/humu.22544, PubMed 24619930

Tran HTT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Andre Holme P (2014)
Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay
Haemophilia, 21 (2), 275-283
DOI 10.1111/hae.12570, PubMed 25521720

Tvedt TH, Holme PA, Bruserud Ø (2014)
[A man in his 80s with muscle stiffness and skin bleeding]
Tidsskr Nor Laegeforen, 134 (10), 1058-61
DOI 10.4045/tidsskr.13.0817, PubMed 24865732

Vandvik PO, Granan LP, Holme PA, Bondi J (2014)
[Antithrombotic therapy in surgery]
Tidsskr Nor Laegeforen, 134 (9), 925
DOI 10.4045/tidsskr.13.1580, PubMed 24828716

Publications 2013

Mathijssen NC, Masereeuw R, Holme PA, van Kraaij MG, Laros-van Gorkom BA, Peyvandi F, van Heerde WL (2013)
Increased volume of distribution for recombinant activated factor VII and longer plasma-derived factor VII half-life may explain their long lasting prophylactic effect
Thromb Res, 132 (2), 256-62
DOI 10.1016/j.thromres.2013.05.027, PubMed 23834817

Tran HT, Sørensen B, Rea CJ, Bjørnsen S, Ueland T, Pripp AH, Tjønnfjord GE, Holme PA (2013)
Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors
Haemophilia, 20 (3), 369-75
DOI 10.1111/hae.12318, PubMed 24251535

Tran HT, Tjønnfjord GE, Holme PA (2013)
Use of thromboelastography and thrombin generation assay to predict clinical phenotype in patients with severe FVII deficiency
Haemophilia, 20 (1), 141-6
DOI 10.1111/hae.12256, PubMed 23992369

van Geffen M, Mathijssen NC, Holme PA, Laros-van Gorkom BA, van Kraaij MG, Masereeuw R, Peyvandi F, van Heerde WL (2013)
Pharmacodynamics of recombinant activated factor VII and plasma-derived factor VII in a cohort of severe FVII deficient patients
Thromb Res, 132 (1), 116-22
DOI 10.1016/j.thromres.2013.04.021, PubMed 23731565

Westberg M, Paus AC, Holme PA, Tjønnfjord GE (2013)
Haemophilic arthropathy: long-term outcomes in 107 primary total knee arthroplasties
Knee, 21 (1), 147-50
DOI 10.1016/j.knee.2013.09.010, PubMed 24156923

Publications 2012

Batorova A, Holme P, Gringeri A, Richards M, Hermans C, Altisent C, Lopez-Fernández M, Fijnvandraat K, European Haemophilia Treatment Standardisation Board (2012)
Continuous infusion in haemophilia: current practice in Europe
Haemophilia, 18 (5), 753-9
DOI 10.1111/j.1365-2516.2012.02810.x, PubMed 22530687

Holmström M, Tran HT, Holme PA (2012)
Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience
Haemophilia, 18 (4), 544-9
DOI 10.1111/j.1365-2516.2012.02748.x, PubMed 22348384

Publications 2011

Enden T, Haig Y, Kløw NE, Slagsvold CE, Sandvik L, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbæk G, Sandset PM, CaVenT Study Group (2011)
Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial
Lancet, 379 (9810), 31-8
DOI 10.1016/S0140-6736(11)61753-4, PubMed 22172244

Ghanima W, Kleven IW, Enden T, Rosales A, Wik HS, Pederstad L, Holme PA, Sandset PM (2011)
Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis
J Thromb Haemost, 9 (6), 1261-3
DOI 10.1111/j.1538-7836.2011.04298.x, PubMed 21489133

Lassila R, Holme PA, Landorph A, Petrini P, Onundarson PT, Hillarp A (2011)
Nordic Haemophilia Council's practical guidelines on diagnosis and management of von Willebrand disease
Semin Thromb Hemost, 37 (5), 495-502
DOI 10.1055/s-0031-1281034, PubMed 22102192

Tran HT, Tjønnfjord GE, Paus A, Holme PA (2011)
rFVIIa administered by continuous infusion during surgery in patients with severe congenital FVII deficiency
Haemophilia, 17 (5), 764-70
DOI 10.1111/j.1365-2516.2011.02596.x, PubMed 21707871

Vetlesen A, Holme PA, Lyberg T, Kjeldsen-Kragh J (2011)
Recovery, survival, and function of transfused platelets and detection of platelet engraftment after allogeneic stem cell transplantation
Transfusion, 52 (6), 1321-32
DOI 10.1111/j.1537-2995.2011.03442.x, PubMed 22084943

Publications 2010

Astermark J, Altisent C, Batorova A, Diniz MJ, Gringeri A, Holme PA, Karafoulidou A, Lopez-Fernández MF, Reipert BM, Rocino A, Schiavoni M, von Depka M, Windyga J, Fijnvandraat K, European Haemophilia Therapy Standardisation Board (2010)
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report
Haemophilia, 16 (5), 747-66
DOI 10.1111/j.1365-2516.2010.02231.x, PubMed 20398077

Ghanima W, Holme PA, Tjønnfjord GE (2010)
[Immune thrombocytopenia--pathophysiology and treatment]
Tidsskr Nor Laegeforen, 130 (21), 2120-3
DOI 10.4045/tidsskr.09.1119, PubMed 21052113

Publications 2009

Astermark J, Negrier C, Hermans C, Holme PA, Klamroth R, Kotsi P, de Moerloose P, Pasi J, Rocino A, von Depka M, Windyga J, Ludlam CA, Interdisciplinary Working Group IDWG (2009)
European curriculum for thrombosis and haemostasis
Haemophilia, 15 (1), 337-44
DOI 10.1111/j.1365-2516.2008.01836.x, PubMed 19149857

Enden T, Kløw NE, Sandvik L, Slagsvold CE, Ghanima W, Hafsahl G, Holme PA, Holmen LO, Njaastad AM, Sandbaek G, Sandset PM, CaVenT study group (2009)
Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency
J Thromb Haemost, 7 (8), 1268-75
DOI 10.1111/j.1538-7836.2009.03464.x, PubMed 19422443

Holme PA, Glomstein A, Grønhaug S, Tjønnfjord GE (2009)
Home treatment with bypassing products in inhibitor patients: a 7.5-year experience
Haemophilia, 15 (3), 727-32
DOI 10.1111/j.1365-2516.2009.02017.x, PubMed 19320748

Perry D, Berntorp E, Tait C, Dolan G, Holme PA, Laffan M, Lassila R, Mumford A, Pasi J, Wilde J, Will A, Yee TT (2009)
FEIBA prophylaxis in haemophilia patients: a clinical update and treatment recommendations
Haemophilia, 16 (1), 80-9
DOI 10.1111/j.1365-2516.2009.02104.x, PubMed 19780845

Vik A, Holme PA, Singh K, Dorenberg E, Nordhus KC, Kumar S, Hansen JB (2009)
Catheter-directed thrombolysis for treatment of deep venous thrombosis in the upper extremities
Cardiovasc Intervent Radiol, 32 (5), 980-7
DOI 10.1007/s00270-009-9655-y, PubMed 19641959

Publications 2008

Brinch L, Tjønnfjord G, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I (2008)
[Allogeneic stem cell transplantation in acute myelogenous leukemia]
Tidsskr Nor Laegeforen, 128 (15), 1681-2; author reply 1682
PubMed 18704137

Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE (2008)
[Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]
Tidsskr Nor Laegeforen, 128 (22), 2563-6
PubMed 19023351

Holme PA, Michelsen AE (2008)
[A 40-year old woman with dizziness and vomiting]
Tidsskr Nor Laegeforen, 128 (12), 1413-5
PubMed 18584769

Negaard HF, Iversen PO, Østenstad B, Iversen N, Holme PA, Sandset PM (2008)
Hypercoagulability in patients with haematological neoplasia: no apparent initiation by tissue factor
Thromb Haemost, 99 (6), 1040-8
DOI 10.1160/TH07-09-0541, PubMed 18521506

Publications 2007

Enden T, Sandvik L, Kløw NE, Hafsahl G, Holme PA, Holmen LO, Ghanima W, Njaastad AM, Sandbaek G, Slagsvold CE, Sandset PM (2007)
Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771)
Am Heart J, 154 (5), 808-14
DOI 10.1016/j.ahj.2007.07.010, PubMed 17967583

Holme PA (2007)
[Deficient thrombosis prophylaxis]
Tidsskr Nor Laegeforen, 127 (9), 1176
PubMed 17479132

Tjønnfjord GE, Holme PA (2007)
Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors
Vasc Health Risk Manag, 3 (4), 527-31
PubMed 17969383

Publications 2005

Holme PA, Brosstad F, Tjønnfjord GE (2005)
Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies
Haemophilia, 11 (5), 510-5
DOI 10.1111/j.1365-2516.2005.01136.x, PubMed 16128896

Publications 1998

Holme PA, Müller F, Solum NO, Brosstad F, Frøland SS, Aukrust P (1998)
Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection
FASEB J, 12 (1), 79-89
DOI 10.1096/fasebj.12.1.79, PubMed 9438413

Holme PA, Solum NO, Brosstad F, Pedersen T, Kveine M (1998)
Microvesicles bind soluble fibrinogen, adhere to immobilized fibrinogen and coaggregate with platelets
Thromb Haemost, 79 (2), 389-94
PubMed 9493596

Sakariassen KS, Holme PA, Orvim U, Barstad RM, Solum NO, Brosstad FR (1998)
Shear-induced platelet activation and platelet microparticle formation in native human blood
Thromb Res, 92 (6 Suppl 2), S33-41
DOI 10.1016/s0049-3848(98)00158-3, PubMed 9886908

Publications 1997

Holme PA, Orvim U, Hamers MJ, Solum NO, Brosstad FR, Barstad RM, Sakariassen KS (1997)
Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis
Arterioscler Thromb Vasc Biol, 17 (4), 646-53
DOI 10.1161/01.atv.17.4.646, PubMed 9108776

Publications 1996

Holme PA (1996)
Studies on human platelet-derived microvesicles: with special reference to their mode of formation, procoagulant properties and clinical relevance
Research Institute for Internal Medicine, Rikshospitalet,University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 970050607, ISBN 82-7722-063-4

Holme PA, Røsger M, Solum NO, Brosstad F, Larsen AM, Hovig T (1996)
Glycoprotein IIb-IIIa on platelet-derived microparticles, and microparticle structures studied by electron microscopy, confocal laser microscopy and crossed radio-immunoelectrophoresis
Platelets, 7 (4), 207-14
DOI 10.3109/09537109609023580, PubMed 21043689

Publications 1995

Holme PA, Brosstad F, Solum NO (1995)
Platelet-derived microvesicles and activated platelets express factor Xa activity
Blood Coagul Fibrinolysis, 6 (4), 302-10
DOI 10.1097/00001721-199506000-00002, PubMed 7548677

Holme PA, Solum NO, Brosstad F, Egberg N, Lindahl TL (1995)
Stimulated Glanzmann's thrombasthenia platelets produced microvesicles. Microvesiculation correlates better to exposure of procoagulant surface than to activation of GPIIb-IIIa
Thromb Haemost, 74 (6), 1533-40
PubMed 8772233

Røger M, Høgåsen K, Holme PA, Halstensen TS, Mollnes TE, Hovig T (1995)
The Fluid-phase SC5b-9 Terminal Complement Complex Binds to the GPIIb/IIIa Complex of Thrombin-stimulated Human Blood Platelets Inhibiting Platelet Aggregation
Platelets, 6 (3), 160-8
DOI 10.3109/09537109509013269, PubMed 21043620

Solum NO, Holme PA, Pedersen TM (1995)
Detection of biotinylated proteins in crossed immunoelectrophoresis gels: studies on platelet membrane receptors and microparticles
Electrophoresis, 16 (8), 1408-13
DOI 10.1002/elps.11501601233, PubMed 8529606

Publications 1994

Holme PA, Solum NO, Brosstad F, Røger M, Abdelnoor M (1994)
Demonstration of platelet-derived microvesicles in blood from patients with activated coagulation and fibrinolysis using a filtration technique and western blotting
Thromb Haemost, 72 (5), 666-71
PubMed 7900071

Publications 1993

Holme PA, Brosstad F, Solum NO (1993)
The difference between platelet and plasma FXIII used to study the mechanism of platelet microvesicle formation
Thromb Haemost, 70 (4), 681-6
PubMed 8115996